SG
BIO icon

Societe Generale’s Bio-Rad Laboratories Class A BIO Stock Holding History

Societe Generale’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		$1.05M Buy
+7,317
New +$1.04M 0.01% 1264

Other funds holding BIO

ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.32B AUM 28.11% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
NIMC
NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return

Societe Generale's BIO Position: Q2 2016 in Review

Societe Generale opened a new position in Bio-Rad Laboratories Class A (BIO) in Q2 2016: 7,317 shares worth $1.05M. The stake represents 0.01% of the portfolio and ranks #1264 among its holdings.

236 funds tracked by Wall St. Rank hold BIO as of Q2 2016.

  • Societe Generale held 7,317 shares of Bio-Rad Laboratories Class A worth $1.05M as of Q2 2016.
  • Bio-Rad Laboratories Class A was a new Societe Generale position in Q2 2016.
  • Bio-Rad Laboratories Class A made up 0.01% of Societe Generale's portfolio in Q2 2016, its #1264 holding.
  • 236 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2016.

Based on Societe Generale's 13F filing for Q2 2016, filed 2 Aug 2016.